Overview

A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if giving Aprepitant 4 hours before and for two days after ERCP decreases the risk of developing pancreatitis after ERCP.
Phase:
N/A
Details
Lead Sponsor:
Duke University
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Aprepitant
Fosaprepitant